Vol 6, No 1 (2019) > Articles >

The Effectivity of Losartan Tablet for Decreasing Fibrotic Tissue Formation in Gastrocnemius Muscle Injury Grade I of Rabbits

Boby Harul Priono , Hermawan Rasyid , Yoyos Ismiarto , Ahmad Ramdan

 

Abstract:

ABSTRACT

Muscle injuries among athletes require a complete recovery to be able to function optimally as before. However, in spite of implementing the management with PRICE (Protection, Rest, Immobilization, Compression and Elevation), during the recovery processes, fibrotic tissue will be formed, which is an unwanted non-functional muscle. Losartan is a blood pressure-lowering drug which has the inhibitory effect of inhibitory effect of TGF-? cytokines (fibrotic tissue regulators). TGF-? is the key to fibrotic formation and differentiation. Losartan has an effect on decreasing the TGF-? production and it may affect the fibrotic tissue. This research is conducted by an experimental comparative method on the rabbit as study objects. Based on Federer formula sampling, twenty samples totally occurred. The random sampling method is adopted for comparing fibrotic tissue in two different groups (control group and losartan group). Losartan is administered orally. There were significant differences in the proportion of fibrotic tissue between the sample groups. The losartan group showed that the level of fibrotic intensity, distribution, and H-score was decreased compared to the control group. Moreover, the result of Mann Whitney statistic test, for determining the H-score for both groups, showed that p is less than 0.05 (p<0.05), which implies that this research is statistically significant. This research proves that giving Losartan tablets brings a significant impact in reducing the formation of muscle fibrosis in muscle injury grade 1 in gastrocnemius rabbits.


Keywords: fibrotic; h-score; losartan; muscle injury grade 1

Published at: Vol 6, No 1 (2019) pages: 46-51

DOI: 10.7454/psr.v6i1.4256


Access Counter: 988 views

Full PDF Download

References:

Aronson, J. K. (2015). Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions: Elsevier.

Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Loeys, B. L. (2007). Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states. Nature medicine, 13(2), 204.

Ekstrand, J., Askling, C., Magnusson, H., & Mithoefer, K. (2013). Return to play after thigh muscle injury in elite football players: implementation and validation of the Munich muscle injury classification. Br J Sports Med, bjsports-2012-092092.

Gal, P., Kilik, R., Mokry, M., Vidinsky, B., Vasilenko, T., Mozes, S., Lenhardt, L. (2008). Simple method of open skin wound healing model in corticosteroid-treated and diabetic rats: standardization of semi-quantitative and quantitative histological assessments. Vet Med, 53(12), 652-659.

Gremmler, B., Kunert, M., Schleiting, H., & Ulbricht, L. (2000). Improvement of cardiac output in patients with severe heart failure by use of ACE‐inhibitors combined with the AT1‐antagonist eprosartan. European journal of heart failure, 2(2), 183-187.

Mann, C. J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A. L., & Muñoz-Cánoves, P. (2011). Aberrant repair and fibrosis development in skeletal muscle. Skeletal muscle, 1(1), 21.

Medicine, A. C. o. S. (2012). ACSM’s resource manual for guidelines for exercise testing and prescription: Lippincott Williams & Wilkins.

Meinen, S., Lin, S., & Ruegg, M. A. (2012). Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A). Skeletal muscle, 2(1), 18.

Nugroho, B. S. (2016). Tingkat Pengetahuan Atlet Tentang Cedera Ankle dan Terapi Latihan di Persatuan Sepak Bola Telaga Utama. Fakultas Ilmu Keolahragaan.

Pessina, P., Cabrera, D., Morales, M. G., Riquelme, C. A., Gutiérrez, J., Serrano, A. L., Muñoz-Cánoves, P. (2014). Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy. Skeletal muscle, 4(1), 7.

Terada, S., Ota, S., Kobayashi, M., Kobayashi, T., Mifune, Y., Takayama, K., Otsuka, T. (2013). Use of an antifibrotic agent improves the effect of platelet-rich plasma on muscle healing after injury. JBJS, 95(11), 980-988.

Trojian, T. H. (2013). Muscle contusion (thigh). Clinics in sports medicine, 32(2), 317-324.

Yang, J., Xue, Q., Miao, L., & Cai, L. (2011). Pulmonary fibrosis: a possible diabetic complication. Diabetes/metabolism research and reviews, 27(4), 311-317.